Huons to Absorb 100% Subsidiary Huons Life Science in Merger

Merger Registration to Be Completed in June

Huons Group will consolidate the pharmaceutical business capabilities within the group under Huons.

Huons Corporate Logo Image. Huons

On April 22, Huons, the pharmaceutical business unit, announced that it has decided on a small-scale merger to absorb its wholly owned subsidiary, Huons Life Science.

The two companies plan to sign the merger agreement on April 23 and, after completing related filings and procedures, finalize the merger by June 2026.

This merger is an absorption-type merger of a wholly owned subsidiary, conducted as a small-scale merger without a capital increase and without issuing new shares. Since no new shares will be issued, there will be no change in management control or change in the largest shareholder after the merger is completed.

The record date for determining shareholders is May 7, and the merger date is scheduled for June 23. The registration process is expected to be completed within June.

Huons decided on the merger to enhance management efficiency by integrating its management resources. In particular, the company plans to restructure its business structure by consolidating the pharmaceutical businesses that had been separated into Huons and Huons Life Science under Huons.

Through this merger, Huons intends to strengthen its overall pharmaceutical business, including contract manufacturing organization (CMO) operations, based on the Osong plant of Huons Life Science.

Suyeong Song, CEO of Huons, said, "By merging, we will be able to combine the core competencies of both companies and further enhance our expertise. We expect to generate synergies such as increased corporate value through management efficiency and performance growth, as well as enhanced shareholder value."

This content was produced with the assistance of AI translation services.